Quick Answer
Q32 Bio Inc. reported Cash and Equivalents of $48.30 million for fiscal year 2025.
Q32 Bio Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $48.30M | -38.1% |
| 2024 | $77.97M | +204.3% |
| 2023 | $25.62M | -24.6% |
| 2022 | $33.99M | -68.6% |
| 2021 | $108.38M | -50.2% |
| 2020 | $217.43M | +304.3% |
| 2019 | $53.77M | +40.7% |
| 2018 | $38.22M | -25.9% |
| 2017 | $51.58M | +352.7% |
| 2016 | $11.39M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $49.04M | -44.9% | -10.6% |
| June 30, 2025 | $54.83M | -43.9% | -16.3% |
| March 31, 2025 | $65.48M | -43.3% | -16.0% |
| December 31, 2024 | $77.97M | +204.3% | -12.5% |
| September 30, 2024 | $89.08M | +145.7% | -8.8% |
| June 30, 2024 | $97.66M | +386.9% | -15.5% |
| March 31, 2024 | $115.51M | +267.8% | +350.9% |
| December 31, 2023 | $25.62M | -24.6% | -29.3% |
- Q32 Bio Inc. showed a decrease of -38.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, Q32 Bio Inc.’s cash and equivalents has grown by 324.0% (from $11.39 million to $48.30 million).
- The most recent figure is from Q32 Bio Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: